Related content

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer

By        

Oncology Reports, Vol. 27, Iss. 6, 2012-01 ,pp. : 2066-2072

Spandidos Publications

Access to resources Recommend Favorite

Is EGF receptor–tyrosine kinase inhibitor therapy in non-small-cell lung cancer patients with EGFR mutations the best option?

By Hayashi Hidetoshi   Nakagawa Kazuhiko  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 441-443

Future Medicine

Access to resources Recommend Favorite

Non-Receptor Tyrosine Kinase Inhibitors in Lung Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 6, 2007-11 ,pp. : 633-642

Bentham Science Publishers

Access to resources Recommend Favorite

Higher Expression of Receptor Tyrosine Kinase Axl, and Differential Expression of its Ligand, Gas6, Predict Poor Survival in Lung Adenocarcinoma Patients

By Ishikawa Masashi   Sonobe Makoto   Nakayama Ei   Kobayashi Masashi   Kikuchi Ryutaro   Kitamura Jiro   Imamura Naoto   Date Hiroshi  

Annals of Surgical Oncology, Vol. 20, Iss. 3, 2013-12 ,pp. : 467-476

Springer Publishing Company

Access to resources Recommend Favorite

Mutational analysis of the insulinlike growth factor 1 receptor tyrosine kinase domain in non-small cell lung cancer patients

By              

Molecular and Clinical Oncology, Vol. 3, Iss. 5, 2015-01 ,pp. : 1073-1079

Science Publishers

Access to resources Recommend Favorite